Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Release's 1Q2024 Financial Statements

<< Previous

Bullboard Posts

Next >>

Comment by Donein25on May 30, 2024 8:29am

151 Views

Post# 36063946

RE:RE:RE:RE:New Press Release - Theralase(R) Release's 1Q2024 Financial Statements

But no mention of 2 year data...which seems to be the new benchmark for FDA. Also, it looks to me like CR% are decreasing accross the board. Can someone confirm that impression? Also, last October they announced Optimization to include additional treatment for recurrence. Why has there been no data on these retreatments? One would think re-reatment would be driving CR % higher.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages